# Key Highlights BY THE Numbers

### **COVID-19 GLOBALLY**

**GLOBAL CASES** (\*WHO APRIL 2021) **GLOBAL DEATHS** 

COVID-19 caused dramatic drops in clinical trials screening, enrollment and participation. This study is designed to quantify those impacts and identify effective mitigation measures with a goal to apply this knowledge to increasing participation in cancer clinical trials moving forward.

#### **LUNG CANCER GLOBALLY**

**GLOBALLY IN 2020 AN ESTIMATED** 

(11.4% OF TOTAL) **NEW LUNG CANCER** CASES WERE DIAGNOSED. **LUNG CANCER REMAINS** THE LEADING CAUSE OF **CANCER DEATH WITH** 

**DEATHS OR 18% OF ALL GLOBAL CANCER DEATHS IN 2020.** 



**LUNG CANCER CLINICAL TRIALS BEING CONDUCTED GLOBALLY** 

#### LUNG CANCER PATIENTS WITH COVID-19 GLOBALLY

COVID-19 has presented major challenges for clinical trial screening, enrollment, and participation. This study is designed to quantify the impacts of COVID-19 on lung cancer interventional clinical trials and identify effective mitigation measures with a goal to apply this knowledge to increasing trial participation moving forward. Current evidence indicates that COVID-19 infections have occurred in 1.5% to 3.5% of actively treated patients with lung cancer, with high rates of morbidity and mortality.

## DYNAMIC DATA STRATEGY



Survey distribution: 1,200 Countries represented: 45 [Regional Distribution map on right]



SECURE TRIAL

trial enrollment data uploads using industry state-of-the-art SFTP to facilitate bulk data uploads from sponsors as well as participating providers



TARGETED INTERVIEWS conducted by experienced oncology consultants will be used to fill any identified data gaps.

The study project's **Executive Committee** membership:

**Ad Hoc Committee** membership:

**Industry** sponsors:

USA 318

> LATIN **AMERICA**

**EUROPE** 369

**MIDDLE EAST** 

AFRICA

RUSSIA

AUSTRALIA. **NEW ZEALAND** 

\*Survey Distribution



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Conquering Thoracic Cancers Worldwide